Nonarteritic, anterior ischemic optic neuropathy is the most common form of ischemic optic neuropathy. 3,4 Typical presentation includes acute, unilateral, and painless loss of central and/or ...

New VA database study is the latest to find a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy.

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...

Please provide your email address to receive an email when new articles are posted on . The deep learning system demonstrated an AUC of 0.97, a sensitivity of 91.1%, a specificity of 93.4% and an ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form ...

As an increasing number of patients come forward with claims that their vision has been permanently impacted by weight loss jabs, eye experts have issued a vital statistical warni ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...

People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 ...

Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide versus non-GLP1-RA meds. (HealthDay News) — Semaglutide is associated with nonarteritic anterior ...

Increase in NAION associated with semaglutide use among individuals with type 2 diabetes. (HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly ...

Sign in to create a free account. No password needed. Enter your email and we’ll send a secure one-click link to sign in. Please enter a valid email address By clicking on any of the sign up options ...